|
|
Article: Cantab Pharmaceuticals Reports Fourth Quarter Results
- Article from:
- PR Newswire
- Article date:
- March 19, 1997
CopyrightCOPYRIGHT 1997 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CAMBRIDGE, England, March 19 /PRNewswire/ -- Cantab Pharmaceuticals plc (Nasdaq: CNTBY) today announced financial results for the fourth quarter and year ended December 31, 1996.
Revenues for the fourth quarter of 1996 were 50,000 Pounds Sterling, compared to 83,000 pounds for the same period in 1995. Revenues in 1996 were 3.1 million pounds, compared to 755,000 pounds in 1995. Most of the 1996 revenues was 3 million pounds in license fees paid by SmithKline Beecham Biologicals (SBBio) in July 1996, with an additional 115,000 pounds received under Cantab's existing research agreement with Pfizer Animal Healthcare Group. In 1995, Cantab's revenues came ...